Prevention trials with tamoxifen may be delayed in USBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6940.1318 (Published 21 May 1994) Cite this as: BMJ 1994;308:1318
- J Roberts
A North American trial to establish whether the antioestrogen drug tamoxifen effectively prevents breast cancer is being threatened with delay because of fears that the drug may be too dangerous for the purpose. The study is being administered by the same group that ran a controversial trial of lumpectomy.
Officials from the National Institutes of Health (NIH), in a hearing last Wednesday before a subcommittee of the US Congress, admitted that breast cancer research leaders had been slow to acknowledge that some patients had been inappropriately entered into a trial that established lumpectomy as effective treatment for early breast cancer (BMJ, 9 April). …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial